GlassScriptPhysician profile
Dave O Stewart
NPI 1588014807
$2,978.61
in general payments reported to CMS, 2019-2025
25 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.99 · 2020: $191 · 2021: $289 · 2022: $423 · 2023: $247 · 2024: $219 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,346.75 | 2025 | |
| Novo Nordisk INC | $299.86 | 2020-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $290.01 | 2020-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $230.85 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $130.71 | 2022 | |
| Dexcom, INC. | $123.42 | 2022-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $103.32 | 2019-2023 | Farxiga |
| Abbvie INC. | $70.47 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.91 | 2023-2025 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.85 | 2023-2024 | Xifaxan |
| Smith+Nephew, INC. | $25.53 | 2019 | |
| Averitas Pharma INC. | $24.34 | 2025 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $24.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.66 | 2022 | |
| Abbott Laboratories | $22.90 | 2025 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $20.84 | 2023 | |
| Sumitomo Pharma America, INC. | $19.93 | 2024 | Aptiom |
| Merck Sharp & Dohme LLC | $19.03 | 2023 | Verquvo, Belsomra |
| Corcept Therapeutics | $18.99 | 2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $15.87 | 2024 | Nuedexta |
| Ibsa Pharma INC. | $15.26 | 2025 | Licart, Tirosint, Flector |
| Paratek Pharmaceuticals, INC. | $15.07 | 2025 | Nuzyra |
| Amgen INC. | $13.58 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.46 | 2022 | |
| Allergan, INC. | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dave Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.